Literature DB >> 15959533

CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations.

S Kumar1, S V Rajkumar, T Kimlinger, P R Greipp, T E Witzig.   

Abstract

Multiple myeloma (MM) is characterized by accumulation of clonal plasma cells (PCs). CD45, a key regulator of antigen-mediated signaling and activation in lymphocytes, is present in early stages of PCs development. We studied CD45 expression on MM PCs by flow cytometry, correlating it to important biological disease characteristics. Additionally, we examined the expression of various adhesion molecules on PCs. A total of 75 patients with untreated MM (29), relapsed MM (17), smoldering MM (12), and monoclonal gammopathy of undetermined significance (MGUS) (17) were studied. The proportion of PCs expressing CD45 was higher among those with early disease (MGUS or smoldering MM) compared to those with advanced disease (new or relapsed MM) (43 vs 22%; P=0.005). Among those with advanced disease, patients with bone lesions had a lower percentage of CD45-positive (CD45+) PCs; 14 vs 34% (P=0.02). Patients with high-grade angiogenesis had a lower percentage of CD45+ PCs; 13 vs 31% (P=0.03). The median overall survival for the CD45+ group (>20% PCs positive) was 39 vs 18 months for the CD45-negative (CD45-) group (P=0.07). The expression of CD138, CD56 and CD54 were higher among the CD45- PCs. This study demonstrates important biological correlates of CD45 expression on myeloma cells. Leukemia (2005) 19, 1466-1470.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15959533     DOI: 10.1038/sj.leu.2403823

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia.

Authors:  Anna Kalff; Tiffany Khong; Meaghan Wall; Malgorzata Gorniak; Sridurga Mithraprabhu; Lynda J Campbell; Andrew Spencer
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

2.  CD19-positive antibody-secreting cells provide immune memory.

Authors:  C J Groves; J Carrell; R Grady; B Rajan; C A Morehouse; R Halpin; J Wang; J Wu; Y Shrestha; R Rayanki; R Kolbeck; Y Wang; R Herbst
Journal:  Blood Adv       Date:  2018-11-27

3.  Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.

Authors:  Huaijian Guo; Mario-Ernesto Cruz-Munoz; Ning Wu; Michael Robbins; André Veillette
Journal:  Mol Cell Biol       Date:  2014-10-13       Impact factor: 4.272

4.  Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.

Authors:  Noriyoshi Iriyama; Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Yoshihito Uchino; Daisuke Kurita; Hitomi Sakagami; Hiromichi Takahashi; Masashi Sakagami; Yujin Kobayashi; Masaru Nakagawa; Shimon Ohtake; Yoshikazu Iizuka; Masami Takei
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

5.  Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.

Authors:  Sang-Yong Shin; Seung-Tae Lee; Hee-Jin Kim; Suk Jin Kim; Kihyun Kim; Eun Suk Kang; Sun-Hee Kim
Journal:  J Clin Lab Anal       Date:  2014-10-02       Impact factor: 2.352

6.  Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.

Authors:  Tae-Dong Jeong; Chan-Jeoung Park; Hyoeun Shim; Seongsoo Jang; Hyun-Sook Chi; Dok Hyun Yoon; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Cheolwon Suh; Kyoo Hyung Lee
Journal:  Korean J Hematol       Date:  2012-12-24

7.  The role of microenvironment in tumor angiogenesis.

Authors:  Domenico Ribatti; Angelo Vacca
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

8.  Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Authors:  R Brown; S Yang; C Weatherburn; J Gibson; P J Ho; H Suen; D Hart; D Joshua
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

9.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Authors:  V Ramakrishnan; M Timm; J L Haug; T K Kimlinger; L E Wellik; T E Witzig; S V Rajkumar; A A Adjei; S Kumar
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

10.  The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.

Authors:  Wilson I Gonsalves; Michael M Timm; S Vincent Rajkumar; William G Morice; Angela Dispenzieri; Francis K Buadi; Martha Q Lacy; David Dingli; Nelson Leung; Prashant Kapoor; Robert A Kyle; Morie A Gertz; Shaji K Kumar
Journal:  Leuk Res       Date:  2016-03-10       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.